



NIH AIDS Reagent Program

20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

Reagent:	Anti-HIV-1 Rev Hybridoma (1G7)
Catalog Number:	7382
Lot Number:	021059
Release Category:	C
Provided:	2 x 10 ⁷ cells/vial. Viability is 88%.
Isotype:	IgG _{2b} , κ light chain.
Propagation Medium:	Ultradoma (BioWhittaker), 95%; FCS, 5%.
Freeze Medium:	Propagation medium (or any standard medium), 80%; FCS, 10%; DMSO, 10%.
Growth Characteristics:	Thaw and treat as standard cells in culture. Split at approximately 5 x 10 ⁵ cells/ml (1:3). The cells grow in small clumps in solution, dependant on growth conditions. Supernatant can be harvested every 2-5 days. For optimal production of antibodies the cells have to be monitored.
Description	P3X63 Ag8.653 myeloma cells
Special Characteristics:	Recombinant HIV-1 Rev used for immunization. Reacts with aa 91-105. Antibodies work by ELISA, Western blot and immunofluorescence. For ELISA and Western blot, a dilution of 1:200 is recommended. For immunofluorescence, the concentration has to be titered. The monoclonal antibody is also available (Catalog #7376).
Sterility:	Negative for mycoplasma, bacteria and fungi.
Recommended Storage:	Liquid nitrogen.

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

Contributor: Dr. Anne Marie Szilvay.

References: Kalland KH, Szilvay AM, Langhoff E, Haukenes G. Subcellular distribution of human immunodeficiency virus type 1 Rev and colocalization of Rev with RNA splicing factors in a speckled pattern in the nucleoplasm. *J Virology* **68**:1475-1485, 1994.

Jensen TH, Jensen A, Szilvay AM, Kjems J. Probing the structure of HIV-1 Rev by protein footprinting of multiple monoclonal antibody-binding sites. *FEBS Lett.* **414**:50-54, 1997

NOTE: Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: Anti-HIV-1 Rev Hybridoma (1G7) from Dr. Anne Marie Szilvay." Also include the references cited above in any publications.

Last Updated August 29, 2017

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.